Emothion (S-Acetyl Glutathione)

Emothion is a stabilized, acetylated form of glutathione (S-Acetyl Glutathione) in which an acetyl group is bonded to the sulfur atom of the cysteine residue, protecting it from oxidation and gastrointestinal degradation. Once absorbed, intracellular deacetylases cleave the acetyl group, releasing free reduced glutathione (GSH) directly inside cells to support antioxidant defense and redox balance.

Origin & History

Emothion (S-Acetyl Glutathione) is a branded, patented crystalline form of S-acetyl-L-glutathione, a synthetic derivative of the tripeptide glutathione where an acetyl group is chemically attached to the cysteine residue's thiol group. It is produced via chemical acetylation of glutathione in laboratory settings and exists in two polymorphic crystalline forms (A and B) with distinct stability and solubility profiles.

Historical & Cultural Context

No historical or traditional medicinal use exists for S-acetyl glutathione, as it is a modern synthetic derivative developed via chemical acetylation for improved stability. While glutathione itself occurs naturally in animals, plants, and microbes, this acetylated form has no roots in traditional medicine systems.

Health Benefits

• Enhanced oral glutathione bioavailability: One crossover trial in 18 healthy volunteers showed superior plasma GSH elevation compared to standard glutathione (evidence: preliminary clinical)
• Cellular antioxidant support: Replenishes intracellular glutathione for free radical defense and redox balance (evidence: mechanistic/theoretical)
• Mitochondrial function support: Maintains GSH levels for mitochondrial action and enzyme maintenance (evidence: mechanistic/theoretical)
• Potential antiviral activity: Preclinical studies suggest anti-HSV-1 activity (evidence: preliminary/in-vitro only)
• Apoptosis modulation: Laboratory studies indicate potential for inducing programmed cell death (evidence: preliminary/in-vitro only)

How It Works

S-Acetyl Glutathione resists hydrolysis by gastrointestinal peptidases that normally degrade unmodified glutathione, enabling intact intestinal absorption via passive diffusion. Inside cells, cytosolic thioesterases and deacetylase enzymes remove the acetyl moiety, regenerating reduced glutathione (GSH), which then serves as a cofactor for glutathione peroxidase (GPx) and glutathione S-transferase (GST) to neutralize reactive oxygen species and detoxify electrophilic compounds. This intracellular GSH replenishment also supports the thioredoxin system and maintains the GSH/GSSG redox ratio, a critical regulator of cellular oxidative stress signaling.

Scientific Research

Clinical evidence is limited to a single-center, randomized, open-label, two-sequence, two-period crossover trial comparing oral bioavailability of Emothion versus standard GSH in 18 healthy volunteers, showing superior plasma GSH elevation with SAG. No large-scale RCTs, meta-analyses, or published PMIDs for human efficacy trials were identified; therapeutic applications remain largely theoretical based on preclinical data.

Clinical Summary

A randomized crossover trial in 18 healthy volunteers demonstrated that oral S-Acetyl Glutathione supplementation produced significantly greater increases in plasma GSH levels compared to unmodified glutathione at equivalent doses, though absolute figures varied by dose and duration. Preclinical studies in cell culture models have confirmed intracellular GSH elevation following S-Acetyl Glutathione treatment, with measurable reductions in markers of oxidative stress such as malondialdehyde (MDA) and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Overall, the human clinical evidence base remains preliminary, consisting primarily of small, short-duration trials, and larger randomized controlled trials with standardized dosing protocols are needed to confirm therapeutic efficacy. Current evidence supports bioavailability superiority over standard glutathione but stops short of establishing definitive clinical outcomes for disease endpoints.

Nutritional Profile

S-Acetyl Glutathione (SAG) is a thioester derivative of the tripeptide L-glutathione (γ-L-glutamyl-L-cysteinyl-glycine) with an acetyl group attached to the sulfhydryl moiety of the cysteine residue, yielding the molecular formula C₁₂H₁₉N₃O₇S (MW ~349.36 g/mol). Typical supplement doses range from 100–300 mg per serving. Unlike reduced glutathione (GSH), the acetyl group protects the thiol from oxidative degradation in the GI tract and enhances lipophilicity, allowing superior intestinal absorption and intracellular delivery. Once absorbed, intracellular thioesterases cleave the acetyl group to liberate free reduced glutathione. Contains no meaningful macronutrients (protein, fat, carbohydrate, fiber) or caloric value at supplemental doses. No vitamins or minerals are inherently present unless added by the formulator. The constituent amino acids (glutamate, cysteine, glycine) are present in peptide-bound form at stoichiometric ratios (~1:1:1 molar). The cysteine-derived sulfur (~9.2% by molecular weight) serves as the functional thiol donor critical for redox activity. Bioavailability notes: Oral bioavailability is substantially higher than standard reduced L-glutathione, which is extensively degraded by gastric acid, intestinal peptidases (γ-glutamyltransferase), and first-pass hepatic metabolism. A crossover pharmacokinetic study in 18 healthy volunteers demonstrated that S-acetyl glutathione produced significantly greater plasma GSH area-under-the-curve (AUC) compared to equimolar unacetylated GSH. The acetylated form resists hydrolysis by GGT in the intestinal brush border, passes intact through enterocytes, and is deacetylated intracellularly by cytoplasmic esterases and acylases. Its enhanced lipophilicity (higher logP than reduced GSH) facilitates passive transcellular absorption. Stability is markedly improved at gastric pH (pH 1.5–3.5) compared to reduced GSH, which rapidly oxidizes to GSSG. No significant food-drug interaction data specific to SAG; however, co-administration with N-acetylcysteine or selenium (as selenomethionine) may synergistically support glutathione peroxidase activity. The product is typically free of common allergens and is suitable for vegetarian/vegan use depending on capsule material.

Preparation & Dosage

The bioavailability trial used a single oral dose of Emothion (exact mg not specified). Commercial products typically feature 300 mg capsules of crystalline Emothion standardized to ≥98% purity in acid-resistant formulations. No standardized daily dosage ranges have been established through multiple clinical studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

N-acetyl cysteine, alpha-lipoic acid, vitamin C, vitamin E, selenium

Safety & Interactions

S-Acetyl Glutathione is generally well tolerated in short-term studies, with no serious adverse events reported at typical supplemental doses ranging from 100 mg to 300 mg per day. Mild gastrointestinal symptoms such as bloating or loose stools have been occasionally noted, consistent with other sulfur-containing compounds. Because glutathione can influence the activity of cytochrome P450 enzymes and Phase II detoxification pathways, theoretical interactions exist with chemotherapy agents such as platinum-based drugs, where elevated intracellular GSH may reduce cytotoxic efficacy. Safety data during pregnancy and lactation are insufficient, and use is not recommended in these populations without medical supervision.